Zoonoses

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant

Retrieved on: 
Tuesday, July 27, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Biocides, Severe acute respiratory syndrome coronavirus 2, Variants of SARS-CoV-2, Antiviral drug, Virucide, COVID-19, Coronavirus, Severe acute respiratory syndrome, GC376

New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure

Key Points: 
  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
    SPL7013, the antiviral agent in VIRALEZE, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
    These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
    VIRALEZE antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.
  • MELBOURNE, Australia, July 27, 2021 /PRNewswire/-- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
  • The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, atThe Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.
  • Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE) are shown in the table below.

Opteev Launches the First-Ever Plug-In Airborne Virus Detector that Immediately Alerts when COVID-19, the Flu and Other Viruses Are Found

Retrieved on: 
Tuesday, July 27, 2021
Health, Medical specialties, Zoonoses, Occupational safety and health, Pandemics, Active fire protection, Americium, Smoke detector, COVID-19, Virus, Influenza

New procedures and technologies are needed to stop the spread of COVID-19 this year while allowing people to enjoy their lives.

Key Points: 
  • New procedures and technologies are needed to stop the spread of COVID-19 this year while allowing people to enjoy their lives.
  • "With ViraWarn, we're making it safer to be together indoors and helping prevent large scale virus transmission in the future."
  • Like a smoke detector monitoring the air and alerting when smoke is detected, ViraWarn monitors the air and immediately alerts when coronavirus particles are detected.
  • The patented sensor technology focuses on the unique electrochemistry of spiked protein viruses, including COVID-19 and influenza, to trigger an alert.

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Coronaviridae, Articles, Sarbecovirus, Health, Zoonoses, Animal virology, Coronavirus, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, Pandemic, Vaccine, COVID-19

Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
  • The NRC technologies, developed with support from the NRCs Pandemic Response Challenge Program, will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
  • Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.
  • Its lantibiotics program features a novel class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.

MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients

Retrieved on: 
Tuesday, July 27, 2021
Occupational safety and health, COVID-19, Public health, Zoonoses, Health

HAIFA, Israel,July 21st,2021 MeMed, a leader in host response-based technologies, today announces that it has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity.

Key Points: 
  • HAIFA, Israel,July 21st,2021 MeMed, a leader in host response-based technologies, today announces that it has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity.
  • MeMed has recently published the results from a multinational derivation study1, demonstrating the signatures ability to accurately predict severe COVID-19 respiratory failure.
  • MeMed COVID-19 Severity will be available in Europe directly from MeMed in our priority countries and through our commercial partner channels in others.
  • The test enables physicians to detect early the likelihood of deterioration in patients affected by COVID-19 and provides a leap forward in COVID-19 patient management.

Global WholeHealth Partners Corp.'s (OTC: GWHP) Antibody IgG/IgM and Antigen Tests That They Offer Are Capable of Detecting the DELTA B.1.617.2, United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) of COVID 19 SARS 2

Retrieved on: 
Monday, July 26, 2021
Medicine, Branches of biology, Medical specialties, Medical tests, Glycoproteins, Zoonoses, Immunologic tests, Chromatography, Rapid antigen test, Antibody, COVID-19, Immunoglobulin G

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM and Antigen tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The government is working with the diagnostics industry to ensure the gains in domestic manufacturing are not lost over time.
  • To conquer COVID and win this war, Global must keep up the research and development of tests.
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.

Ondine Biomedical to present results on the effects of its upper airways decolonization technology for SARS-CoV-2 eradication at ICPIC 2021

Retrieved on: 
Monday, July 26, 2021
Sarbecovirus, Zoonoses, Viruses, Respiratory diseases, Severe acute respiratory syndrome

Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.

Key Points: 
  • Canadian medical technology innovator, Ondine Biomedical, will be presenting results from a successful in vitro study of its pioneering Steriwave upper airway disinfection technology against SARS-CoV-2 at the International Conference on Prevention and Infection Control (ICPIC) in Geneva, on 15th September 2021.
  • The presentation will focus on results demonstrating that this patented photodisinfection therapy can rapidly destroy the RNA genome of SARS-CoV-2.
  • The nose and upper airway have been identified as ideal breeding grounds and reservoirs for many threatening pathogens including MRSA, Candida auris, and SARS-Cov-2.
  • Ondines Steriwave photodisinfection therapy can rapidly and painlessly eradicate pathogens in the nose and upper airway, helping to eliminate a leading source of infection and transmissions.

SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis

Retrieved on: 
Monday, July 26, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Biotechnology, Coronaviridae, Sarbecovirus, Zoonoses, Variants of SARS-CoV-2, Variant of concern, Molecular diagnostics, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, DiaSorin

Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC).

Key Points: 
  • Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC).
  • Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
  • For more information on SpeeDx please see: https://plexpcr.com
    SARS-CoV-2 Variant Classifications and Definitions.

Voluntary Recall Notice of McCormick Italian Seasoning products and Frank's RedHot Buffalo Ranch Seasoning due to Possible Salmonella Risk

Retrieved on: 
Monday, July 26, 2021
Infectious diseases, Medical specialties, Clinical medicine, Gram-negative bacteria, Pathogenic bacteria, Salmonella, Zoonoses, McCormick & Company, Frank's RedHot, McCormick

HUNT VALLEY, Md., July 26, 2021 /PRNewswire/ -- McCormick & Company, Inc. is initiating a voluntary recall of McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning due to possible contamination with Salmonella.

Key Points: 
  • HUNT VALLEY, Md., July 26, 2021 /PRNewswire/ -- McCormick & Company, Inc. is initiating a voluntary recall of McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning due to possible contamination with Salmonella.
  • Healthy persons infected with Salmonella often experience fever, diarrhea, nausea, vomiting and abdominal pain.
  • In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses.
  • bottle
    The four products were shipped to the following locations:
    The potential risk was brought to McCormick's attention by FDA during routine testing.

Israeli start-up ONYX radiance launches Covid-19 eliminating and skin-rejuvenating face mask

Retrieved on: 
Monday, July 26, 2021
Health, Medical specialties, Medicine, Zoonoses, Antiviral drug, Biocides, Acne, Influenza, Orthomyxoviridae, Virus

The Antiviral Defense Mask maintains its efficiency in destroying >99% of the Covid-19 virus, Influenza virus, and bacteria,after50 regular home laundries.

Key Points: 
  • The Antiviral Defense Mask maintains its efficiency in destroying >99% of the Covid-19 virus, Influenza virus, and bacteria,after50 regular home laundries.
  • The Anti-viral results have been verified by a qualified independent laboratory in accordance with the ISO18184 test protocol.
  • ONYX radiance eyes on becoming a global leading technological consumer textile brand of high-end textile products that provide its users with substantial Health & Beauty benefits.
  • Customers of ONYX radiance are continuously reporting on significant improvement in their skin's health and appearance, on alleviation of severe Acne conditions, and on much improved sleep quality.

Anivive's GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment

Retrieved on: 
Friday, July 23, 2021
Antiviral drugs, Medical specialties, Health, Zoonoses, GC376, COVID-19, Virus, Protease inhibitor, Vaccine, Rupintrivir, 3CLpro-1

While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.

Key Points: 
  • While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.
  • GC376 is a protease inhibitor, designed to block the replication process and stop the virus from spreading.
  • GC376 has the potential to be a One Health medicine, providing therapeutic benefits to both pets and people.
  • Anivive has filed a pre-Investigational New Drug request with the Food and Drug Administration to evaluate GC376 as a post-infection treatment of COVID-19 in humans.